Biotech Startups

Vascugen develops an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell therapy intended to form new blood vessels and restore microvascular circulation in oxygen-starved tissues. It targets diabetic and arterial disease patients at high risk of limb amputation, and handles development from R&D through cGMP manufacturing.

1 investor

Vasomune is a clinical-stage biotech company developing therapeutic treatments for vascular and immune-related diseases. The company focuses on bringing drug candidates like AV-001 from laboratory research to clinical applications for patients with serious conditions.

1 investor

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines built on its own delivery platform, designed to produce mucosal and systemic immunity against common viral diseases. Its pipeline includes a norovirus vaccine program.

1 investor

Transforming vaccine and therapeutic delivery through the MIMIX patch.

1 investor

VAXIMM is a clinical-stage biopharmaceutical company developing oral T-cell immunotherapies for cancer, based on technology invented at UC San Diego. Its lead candidate VXM01 has been evaluated in clinical trials for indications such as pancreatic cancer, and the company operates as a subsidiary of OSR Health.

1 investor

1 investor

VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies. It targets infectious diseases such as hepatitis B, COVID-19, and cytomegalovirus, as well as cancers including glioblastoma.

1 investor

Enna develops natural neuro-pharmaceuticals for mental wellness, using bio-tracking, data science, and machine learning to support drug development and formulation optimization. Its pipeline includes beta-carboline-based formulations (SVEN1 and SVEN2) inspired by eastern medicine traditions and intended for clinical group therapy.

1 investor

VC Gene Therapy develops gene therapies, with a first pipeline using genome editing to treat autosomal dominant inherited retinal degenerative diseases and aiming to begin clinical trials. It is a subsidiary of Vision Care Inc. and part of the Vision Care Group, based in Kobe, Japan.

1 investor

Vcreate uses machine learning and single-cell sequencing screening assays to engineer human T-cell receptors (TCRs) for TCR-based therapies that target disease-specific antigens, including rare cancer mutations. Its platform screens hundreds of millions of TCR-antigen interactions to design receptors that activate against targets inside cells that are otherwise difficult to drug.

1 investor

Vectech develops AI-powered vector identification and surveillance technologies to support public health interventions and targeted mosquito control during disease outbreaks. The company serves public health organizations and disease prevention agencies globally.

1 investor

Vector Biomed develops lentiviral vectors for cell and gene therapy, focusing on affordable, scalable vector solutions with transparent pricing and no hidden royalties. It positions itself as a manufacturing and development partner for researchers and therapeutic developers.

1 investor

Vectron Biosolutions develops custom bacterial production strains for protein manufacturing, using proprietary technologies (VB Expression, VB Evolution, and VB Secretion) to engineer E. coli and other microorganisms for clients in the pharmaceutical and biotech industries.

1 investor

Veil Therapeutics develops "stealth biologics" using a PEG-based bottlebrush polymer platform (the Veil Platform) designed to extend drug half-life and stability while evading immune recognition. Its lead program, VTx-101, is a polymer-conjugated uricase for treating chronic gout, with the platform also applicable to proteins, peptides, lipid nanoparticles, and aptamers.

1 investor

Veirulence develops first-in-class non-antibiotic small molecule therapeutics that target bacterial virulence factors to treat resistant infections, with an initial focus on the WHO priority pathogen Pseudomonas aeruginosa. The company aims to address antimicrobial resistance in hospital-acquired bacterial infections.

1 investor

Velico is a clinical-stage medical technology company developing a spray-dried "dry plasma" manufacturing system that enables blood centers to produce point-of-care plasma products for transfusion. Its products are aimed at pre-hospital, military, ambulance, and mass-casualty settings to reduce preventable death from bleeding.

1 investor

Vella Bioscience develops products for women's sexual and reproductive health using nano-encapsulated liposomal cannabidiol and liposome-based biotech to improve absorption of active ingredients, with a focus on female arousal, orgasm, and related pain. Its work spans the broader landscape of women's sexual and reproductive medicine.

1 investor

Veloxis Pharmaceuticals is a specialty pharmaceutical company that develops therapies and programs for the prevention of organ rejection in transplant patients, serving transplant healthcare providers and the patients they treat. It is part of Asahi Kasei Corporation and is advancing investigational immunosuppressive agents for kidney and heart transplant recipients.

1 investor

veMico develops postbiotics — bioactive compounds derived from probiotic bacteria — that act on the host's immune system and gut barrier to improve gut health. It offers product development, bioactive licensing, and research collaboration for partners in the gut health and nutrition space.

1 investor

1 investor

Ventora Medical develops a neonatal airway pressure monitoring device for clinicians managing non-invasive respiratory support in newborn patients. The device provides continuous, accurate measurement of airway pressure delivered by CPAP and high-flow nasal cannula systems.

1 investor

1 investor

VeraMorph is a drug delivery company that has developed a proprietary oral drug delivery platform used to improve solubility and clinical translation of poorly soluble compounds. It works with pharmaceutical companies and is building a portfolio of clinically differentiated oral versions of approved drugs.

1 investor

Veranova is a contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), including highly potent APIs, drug linkers, and complex small molecule chemistry. It provides process and analytical development, solid form sciences, and scale-up to commercial manufacturing for pharmaceutical companies developing small molecule drugs.

1 investor